Compare Regeneron Pharmaceuticals Inc (REGN) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while United Microelectronics Corp trades at $23.13 (market cap $58.54B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and United Microelectronics Corp pays the higher dividend (1.72%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and United Microelectronics Corp for 42 Days on average.
| REGN | UMC | |
|---|---|---|
Market Cap | $76.40B | $58.54B |
Volume | 626,381 | 8,050,715 |
Sector | Health | Technology |
52-Week High | $852.03 | $28.02 |
52-Week Low | $557.73 | $7.02 |
Typical Hold Time | 107 Days | 42 Days |
Enterprise Value | $71.12B | $55.62B |
Dividend Yield | 0.51% | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
UMC trades at $22.82, down 1.6% on the day, with a bullish technical signal despite mixed moving average indicators. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 estimate. Revenue growth remains steady, projected to reach $250.7B in 2026, while net income margin is expected to rebound to 32.75%. Recent news highlights strong AI-driven demand and specialty chip expansion.
UMC presents a mixed investment case with strong earnings momentum and AI growth potential offset by declining profit margins and competitive pressures. The stock appears moderately valued with a P/E of 22.48, while analyst consensus leans Hold (53.33%) with some institutional selling activity. Key risks include semiconductor cycle volatility and AI spending concerns impacting foundry stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
